Allogene Therapeutics Inc to Review The Potential Innovation of Allogeneic CAR T Therapy in Multiple Myeloma Transcript
Welcome to the Allogene Therapeutics webinar to discuss initial results from our Phase I UNIVERSAL study of ALLO-715 in relapsed/refractory multiple myeloma presented today at the American Society of Hematology. We're looking forward to discussing data from our second program that highlights progress towards our goal of making AlloCAR T therapy a reality for patients.
Today's call is being webcast on our website and will be available for replay. Before the start of this webinar, I'd like to note that we issued a press release that provides the details of this data. We've also posted the materials that will be presented during the webinar on our website at www.allogene.com under the Investor Relations section. After our formal presentation, I will open up the call for questions.
On the call today will -- are Dr. David Chang and Dr. Rafael Amado. We're also pleased to have Dr. Parameswaran Hari from the Medical College of Wisconsin joining us
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
